90% of drug candidates selected in the preclinical phases fail in the clinical assays on Man, mainly for efficacy or safety issues which have not been previously detected. This has a huge economic impact on the pharmaceutical / biotech companies but also on patients, who are waiting for the innovative treatments they need.
This huge attrition rate indicates a lack of efficient tools at the early stages of development to evaluate correctly their new molecules, when researchers and developers must take strategic “go / no go” decisions about their projects.
To help researchers to evaluate better their news drugs at early stages, Nanobiose created SecretCells®, a disposable lab-on-a-chip which combines 3D cell culture capacities to better mimic in-vivo like conditions with the simultaneous real-time capture of up to 9 secreted biomarkers.
Nanobiose also offers services, with a unique service based on its proprietary technology to assess the inflammation / activation of human macrophages in vitro and a comprehensive support for immunotoxicology and immunological assessments.
Nanobiose is a specialized company founded in july 2016 near Chambéry (France), at the alpine crossroads of Europe. Nanobiose is developing innovative lab-on-a-chip solutions for improved in vitro evaluation of the activity/safety of new molecular entities at an early stage ranging from:
Nanobiose also provides services to the industry in the field of immunotoxicology and immunological assessments.